Stock AnalizDianthus Therapeutics, Inc. DNTH
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Dianthus Therapeutics, Inc. (DNTH) is a healthcare company listed in the US with a market value of about $5.2B. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$202M, a net margin of -7436.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $2M | $6M | $3M | — | — | — | $0 | $0 | $0 | $0 |
| Net income | -$202M | -$162M | -$85M | -$44M | -$28M | -$71M | -$75M | -$77M | -$58M | -$35M | -$9M |
| Free cash flow | -$176M | -$129M | -$78M | -$37M | -$29M | -$61M | -$64M | -$60M | -$50M | -$24M | -$7M |
| EPS (diluted) | $-4.08 | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-87.61 | $-116.13 | $-140.58 | $-212.57 | $-1298.51 | $-4424.57 |
| Net margin | -7436.5% | -7973.3% | -1362.8% | -1541.2% | — | — | — | — | — | — | — |
| ROIC | — | -28.4% | -22.7% | -22.5% | — | — | -43.2% | -46.4% | -32.5% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $139.25, 52% above the current price; targets range from $113.00 to $200.00; the consensus rating is “Strong buy”; expected EPS is $-3.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Dianthus Therapeutics pay a dividend?
Not currently.
Is Dianthus Therapeutics a good stock to buy?
We do not give buy or sell advice. Dianthus Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.